Conceptual illustration of Kissei’s portfolio strategy, showing clinical evidence review, research platforms, a Kissei sign and Japan’s flag.
Kissei’s Tavneos setback is putting pressure on its growth plans. What could this mean for international suppliers and licensing partners? We examine the company’s pipeline, the importance of reliable evidence and how to approach Kissei with a credible Japan proposition.